1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

文獻(xiàn)： 1、Journal of Organic Chemistry1961vol. 26p. 2507 - 2510 2、J Contemp Dent Pract. 2016 Dec 1;17(12):1009-1012.Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis.Baptist J1, Shakya S2, Ongole R1. 3、heart failure with preserved ejection fraction：types 1 and 2 ？10.1016/j.jchf.2018.12.017 4、Current status of research on infantile cholestatic liver disease in China: a visualization analysis Author(s): LIAO Qiong, WAN Chao-Min, ZHU Yu, YANG Xiao-Yan, SHU Min, Department of Pediatrics, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University 5、Diagnosis and differential diagnosis of infantile cholestasis disease Author(s): Dong Chen, Huang ZhihuaDong Chen: Department of Pediatrics, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China 6、In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.Kim YH1, Choi KS, Kam SH, Lee KH, Park JS 7、Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers. Niopas I1, Daftsios AC, Nikolaidis N. 8、PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial；（新型口服碳青霉烯類抗生素替比培南匹伏酯（ME1211）在耳鼻咽喉感染中的pk/pd分析，一項Ⅱ期臨床試驗） 9、PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial；（新型口服碳青霉烯類抗生素替比培南匹伏酯（ME1211）在耳鼻咽喉感染中的pk/pd分析，一項Ⅱ期臨床試驗） 10、Trends in the Management of Acute Heart Failure Requiring Intensive Care Shirakabe A Kobayashi N, kazakh Matsushita M, Shibata Y -, Godah, Shigihara s", AsanKiuchit 11、Patient Selection for Tolvaptan Therapy Among Those With Chronic Kidney Disease and Heart Failure 12、Baumann;?Butler;   [更多]

新版醫(yī)保目錄需求說明書。   [更多]

1、Ophthalmic viscosurgical devices Article· Literature Review?in?Current Opinion in Ophthalmology 19(1):50-4 · February 2008?with?82 Reads DOI: 10.1097/ICU.0b013e3282f14db0 · Source: PubMed 2、Lancet Psychiatry. 2019 Mar;6(3):211-224. doi: 10.1016/S2215-0366(18)30511-X. Epub 2019 Feb 18. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Huang Y1, Wang Y2, Wang H3, Liu Z4, Yu X4, Yan J5, Yu Y6, Kou C6, Xu X7, Lu J7… PMID:30792114 3、Prevalence of myopia in local and international schools in Hong Kong. 4、Effects of different concentrations of atropine on controlling myopia in myopic children. 5、Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys 6、Effects of different concentrations of atropine on controlling myopia in myopic children. 7、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 8、Safety and effectiveness of tolvaptan administration after total arch replacement Yasunori Iida, MD, PhD, Akihiro Yoshitake, MD, PhD, Hideyuki Shimizu, MD, PhD 9、The role of tolvaptan administration after cardiac surgery: ameta-analysisIoannis Bellos MD , Dimitrios C. Iliopoulos MD, PhD ,Despina N. Perrea MD, PhD 10、Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets.Tulain U, Ur-Rahman N.Pak J Pharm Sci. 2008 Apr;21(2):131-8. 11、Relative bioavailability and bioequivalence study of theophylline sustained release formulations. Vergin H, Mahr G, Winterhalter B, Wigand R.Arzneimittelforschung. 2003;53(9):635-9. 12、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 13、journal of medicinal chemistry 2004,47,530 14、Gupta AK, Ryder JE, Lynch LE et al. The use   [更多]

求DOF期刊2018年10-12期文獻(xiàn)   [更多]

1、收集全國31個省市自治區(qū)官方的藥品或藥械采購平臺公布的藥品中標(biāo)信息。 2、工作內(nèi)容：及時查到最新公布的藥品中標(biāo)文件信息，并將最新的文件按指定要求 處理成規(guī)范的格式(excel表)。交稿如發(fā)現(xiàn)遺漏，反饋后望及時補(bǔ)充，若有錯誤，也會進(jìn)行相應(yīng)的記錄和費(fèi)用扣除。 3、長期合作(一年以上) 本次補(bǔ)充月份：2020年8月-2021年1月（共6個月）   [更多]

我目前手里有數(shù)據(jù)，但沒有軟件可以分析,求購waters公司的質(zhì)譜軟件，我安裝來分析處理數(shù)據(jù)。 要求如下： 1、收到軟件并安裝成功后支付賞金。 2、或者幫忙分析數(shù)據(jù)也行，價格可商量。   [更多]

此需求專門獎勵提共了2011年和2004年的有關(guān)信息的威客   [更多]

急需液體敷料一類醫(yī)療器械備案全套申請資料及生產(chǎn)備案資料 產(chǎn)品風(fēng)險分析報告 產(chǎn)品技術(shù)要求 產(chǎn)品檢驗報告 臨床評價資料 產(chǎn)品說明書及標(biāo)簽樣稿 與生產(chǎn)研制、生產(chǎn)有關(guān)的質(zhì)量管理體系文件 生產(chǎn)制造信息 符合性聲明   [更多]

求購國家藥品數(shù)據(jù)庫，有現(xiàn)成的請?zhí)峁?   [更多]